Submission from Allergy & Anaphylaxis Australia (A&AA): We welcome the opportunity to lodge our comments in support of the submission for Jorveza® (Budesonide) which is on the March 2023 Pharmaceutical Benefits Advisory Committee (PBAC) meeting agenda. Jorveza® was PBS listed in May 2022 specifically for the treatment of EoE.

This application is for a change to the current Pharmaceutical Benefits Scheme (PBS) listing, for Jorveza® tablet 500 micrograms or tablet 1 mg (orally disintegrating) for eosinophilic oesophagitis (EoE). The proposed changes address issues in the current listing which are potentially reducing access to Jorveza® for some patients with EoE.

These issues are:

• The requirement for a gastroenterologist to prescribe Jorveza®
• The requirement for endoscopy to confirm improvement with Jorveza®
• Uncertainty about the number of biopsies required at endoscopy to initiate treatment with Jorveza®

See the submission here:

Submission concerning Jorveza® (Budesonide) for EoE change to current PBS listing - 23 Jan 2023318.08 KB